🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

7,888 results for “1” Clear

  1. [18F]-AlF-FAPI-74

    Disc Medicine

    Carcinoma of Unknown Primary

    phase 3 small molecule active

    1 trial

  2. [18F]-AlF-FAPI-74

    Disc Medicine

    Advanced gastric cancer

    phase 3 small molecule active

    1 trial

  3. [18F]-AlF-FAPI-74, GlucaGen®, HypoKit met 1 mg poeder en oplosmiddel voor oplossing voor injectie, Scopolamine butylbromide Kalceks 20 mg/ml oplossing voor injectie

    Disc Medicine

    Cholangiocarcinoma

    phase 3 small molecule active

    1 trial

  4. [18F]MNI-659

    Pari Pharma GmbH

    Patients with symptomatic and pre-symptomatic Huntington's disease

    phase 3 small molecule active

    1 trial

  5. [68Ga]Ga-PentixaFor

    Disc Medicine

    Primary aldosteronism

    phase 3 small molecule active

    1 trial

  6. [68Ga]Ga-PentixaFor

    Pari Pharma GmbH

    Primary aldosteronism, Primary aldosteronism

    phase 3 small molecule active

    1 trial

  7. [68Ga]Ga-PentixaFor, FLUDEOXYGLUCOSE (18F)

    Alphapharm Pty Ltd

    Marginal Zone Lymphoma

    phase 3 small molecule active

    1 trial

  8. alpha1-proteinase inhibitor

    Takeda

    Covid19

    phase 3 small molecule terminated

    1 trial

  9. alprazolam, Placebo matching Staccato® alprazolam and without active substance

    Lacuna Pharma Pty Ltd

    Treatment of stereotypical prolonged seizure

    phase 3 small molecule active

    1 trial

  10. balcinrenone/dapagliflozin 15 mg/10 mg and matching placebo for dapagliflozin 10 mg

    AstraZeneca

    Heart Failure and Impaired Kidney Function

    phase 3 small molecule active

    1 trial

  11. batch 1 of Group ACYW135 Meningococcal Conjugate Vaccine (CRM197) (MCV4)

    CanSino Biologics

    Meningococcal Meningitis

    phase 3 mab active

    1 trial

  12. bimekizumab

    Lacuna Pharma Pty Ltd

    Psoriatic Arthritis

    phase 3 small molecule active

    1 trial

  13. bimekizumab

    Lacuna Pharma Pty Ltd

    Axial Spondyloarthritis

    phase 3 small molecule active

    1 trial

  14. bimekizumab, Skyrizi 150 mg solution for injection in pre-filled syringe, Placebo matching test and comparator. 0.9% sodium chloride solution for injection (unauthorized).

    Lacuna Pharma Pty Ltd

    Psoriatic arthritis

    phase 3 small molecule active

    1 trial

  15. bococizumab (PF-04950615)

    Pfizer

    Cardiovascular Disease

    phase 3 small molecule terminated

    1 trial

  16. brivaracetam, -, -, brivaracetam, -, brivaracetam, Placebo matching < brivaracetam oral solution> and without active substance

    Lacuna Pharma Pty Ltd

    Childhood Absence Epilepsy Juvenile Absence Epilepsy

    phase 3 small molecule active

    1 trial

  17. camizestrant, Arimidex® 1 mg Filmtabletten, IBRANCE 75 mg hard capsules, Placebo to match camizestrant, Placebo to match Arimidex, LEUPRORELIN ACETATE, IBRANCE 125 mg hard capsules, IBRANCE 75 mg film-coated tablets, IBRANCE 100 mg hard capsules, IBRANCE 75 mg hard capsules, IBRANCE 100 mg hard capsules, IBRANCE 125 mg film-coated tablets, IBRANCE 100 mg film-coated tablets, IBRANCE 125 mg hard capsules, IBRANCE 100 mg hard capsules, Camizestrant, IBRANCE 125 mg hard capsules, IBRANCE 75 mg hard capsules, G

    AstraZeneca AB

    Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer

    phase 3 small molecule active

    1 trial

  18. candesartan

    Takeda

    Type 1 Diabetes

    phase 3 small molecule completed

    1 trial

  19. candesartan cilexetil

    Takeda

    Type 1 Diabetes

    phase 3 small molecule completed

    1 trial

  20. casirivimab+imdevimab combination therapy

    Regeneron UK Limited

    COVID-19

    phase 3 small molecule terminated

    1 trial

  21. centrally blinded product containing all the same manufactured ingredients and excipients as the DM199 formulation, except for the active pharmaceutical ingredient (API).

    DiaMedica Therapeutics

    Acute Ischemic Stroke

    phase 3 small molecule active

    1 trial

  22. chemotherapy and SHR-1316(Adebrelimab) comnined with surgery or radiotherapy

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Limited Stage Small Cell Lung Cancer

    phase 3 other active

    1 trial

  23. ciclesonide (XRP1526)

    Takeda

    Respiratory Tract Diseases

    phase 3 small molecule completed

    1 trial

  24. cleminorexton

    Centessa Pharmaceuticals plc

    Narcolepsy Type 1

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources